Genetic and epigenetic signatures of breast cancer subtypes

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 3, 2012, Pages 934-949

  Stecklein, Shane R ^a   Jensen, Roy A ^a   Pal, Arindam ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Basal like breast cancer; BRCA1; Breast cancer; Cancer stem cell; DCIS; Epigenetics; MiRNA; Review; Triple negative breast cancer

Indexed keywords

ALPHA6 INTEGRIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 18; CYTOKERATIN 8; DNA (CYTOSINE 5) METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE P1; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; MICRORNA 107; MICRORNA 10B; MICRORNA 126; MICRORNA 200; MICRORNA 200C; MICRORNA 21; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR ZEB1; TUMOR MARKER; UVOMORULIN;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STEM CELL; CANCER SURVIVAL; DNA METHYLATION; EPIGENETICS; GENE DOSAGE; GENETIC RISK; HISTONE MODIFICATION; HUMAN; INTRADUCTAL CARCINOMA; LUMINAL TYPE A BREAST CANCER; LUMINAL TYPE B BREAST CANCER; LUMINAL TYPE C BREAST CANCER; NONHUMAN; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; BREAST TUMOR; FEMALE; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; REVIEW;

BREAST NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; HUMANS; NEOPLASTIC STEM CELLS;

EID: 84860866693     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (175)

1. Coughlin, S. S. & D. U. Ekwueme: Breast cancer as a global health concern. Cancer Epidemiol, 33, 315-8 (2009)
2. Hennessy, B. T., A. M. Gonzalez-Angulo, K. Stemke-Hale, M. Z. Gilcrease, S. Krishnamurthy, J. S. Lee, J. Fridlyand, A. Sahin, R. Agarwal, C. Joy, W. Liu, D. Stivers, K. Baggerly, M. Carey, A. Lluch, C. Monteagudo, X. He, V. Weigman, C. Fan, J. Palazzo, G. N. Hortobagyi, L. K. Nolden, N. J. Wang, V. Valero, J. W. Gray, C. M. Perou & G. B. Mills: Characterization of a naturally occurring breast cancer subset enriched in epithelial-tomesenchymal transition and stem cell characteristics. Cancer Res, 69, 4116-24 (2009)
3. Perou, C. M., T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown & D. Botstein: Molecular portraits of human breast tumours. Nature, 406, 747-52 (2000)
4. Sorlie, T., C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. Eystein Lonning & A. L. Borresen-Dale: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869-74 (2001) (Pubitemid 32878711)
5. Sotiriou, C., S. Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat, S. B. Fox, A. L. Harris & E. T. Liu: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A, 100, 10393-8 (2003) (Pubitemid 37071889)
6. Park, C. H., D. E. Bergsagel & E. A. McCulloch: Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst, 46, 411-22 (1971)
7. Lobo, N. A., Y. Shimono, D. Qian & M. F. Clarke: The biology of cancer stem cells. Annu Rev Cell Dev Biol, 23, 675-99 (2007)
8. Sell, S.: Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol, 51, 1-28 (2004) (Pubitemid 38781748)
9. Huntly, B. J. & D. G. Gilliland: Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer, 5, 311-21 (2005) (Pubitemid 40488636)
10. Dalerba, P., R. W. Cho & M. F. Clarke: Cancer stem cells: models and concepts. Annu Rev Med, 58, 267-84 (2007) (Pubitemid 46706514)
11. Clarke, M. F. & M. Fuller: Stem cells and cancer: two faces of eve. Cell, 124, 1111-5 (2006)
12. Reya, T., S. J. Morrison, M. F. Clarke & I. L. Weissman: Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11 (2001) (Pubitemid 33041634)
13. Behbod, F. & J. M. Rosen: Will cancer stem cells provide new therapeutic targets? Carcinogenesis, 26, 703-11 (2005) (Pubitemid 41214332)
14. Bruce, W. R. & H. Van Der Gaag: A Quantitative Assay for the Number of Murine Lymphoma Cells Capable of Proliferation in vivo. Nature, 199, 79-80 (1963)
15. Fiala, S.: Cancer Cell as a Stem Cell Unable to Differentiate . A Theory of Carcinogenesis. Neoplasma, 15, 607-& (1968)
16. Bonnet, D. & J. E. Dick: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 3, 730-7 (1997) (Pubitemid 27298715)
17. Pierce, G. B. & C. Wallace: Differentiation of malignant to benign cells. Cancer Res, 31, 127-34 (1971)
18. Hamburger, A. & S. E. Salmon: Primary bioassay of human myeloma stem cells. J Clin Invest, 60, 846-54 (1977) (Pubitemid 8208477)
19. Hamburger, A. W. & S. E. Salmon: Primary bioassay of human tumor stem cells. Science, 197, 461-3 (1977)
20. Fialkow, P. J.: Stem cell origin of human myeloid blood cell neoplasms. Verh Dtsch Ges Pathol, 74, 43-7 (1990)
21. Spangrude, G. J., S. Heimfeld & I. L. Weissman: Purification and characterization of mouse hematopoietic stem cells. Science, 241, 58-62 (1988)
22. Lapidot, T., C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M. A. Caligiuri & J. E. Dick: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645-8 (1994) (Pubitemid 24067706)
23. Singh, S. K., I. D. Clarke, T. Hide & P. B. Dirks: Cancer stem cells in nervous system tumors. Oncogene, 23, 7267-73 (2004) (Pubitemid 39382160)
24. Singh, S. K., C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R. M. Henkelman, M. D. Cusimano & P. B. Dirks: Identification of human brain tumour initiating cells. Nature, 432, 396-401 (2004) (Pubitemid 39551674)
25. Al-Hajj, M., M. S. Wicha, A. Benito-Hernandez, S. J. Morrison & M. F. Clarke: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 100, 3983-8 (2003) (Pubitemid 36418143)
26. Fang, D., T. K. Nguyen, K. Leishear, R. Finko, A. N. Kulp, S. Hotz, P. A. Van Belle, X. Xu, D. E. Elder & M. Herlyn: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res, 65, 9328-37 (2005) (Pubitemid 41508000)
27. Gibbs, C. P., V. G. Kukekov, J. D. Reith, O. Tchigrinova, O. N. Suslov, E. W. Scott, S. C. Ghivizzani, T. N. Ignatova & D. A. Steindler: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia, 7, 967-76 (2005)
28. Ricci-Vitiani, L., D. G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle & R. De Maria: Identification and expansion of human colon-cancerinitiating cells. Nature, 445, 111-5 (2007) (Pubitemid 46067311)
29. O'Brien, C. A., A. Pollett, S. Gallinger & J. E. Dick: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106-10 (2007) (Pubitemid 46067310)
30. Ginestier, C., M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M. S. Wicha & G. Dontu: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-67 (2007) (Pubitemid 350056407)
31. Fearon, E. R. & B. Vogelstein: A genetic model for colorectal tumorigenesis. Cell, 61, 759-67 (1990)
32. Grander, D.: How do mutated oncogenes and tumor suppressor genes cause cancer? Med Oncol, 15, 20-6 (1998) (Pubitemid 28248295)
33. Creighton, C. J., X. Li, M. Landis, J. M. Dixon, V. M. Neumeister, A. Sjolund, D. L. Rimm, H. Wong, A. Rodriguez, J. I. Herschkowitz, C. Fan, X. Zhang, X. He, A. Pavlick, M. C. Gutierrez, L. Renshaw, A. A. Larionov, D. Faratian, S. G. Hilsenbeck, C. M. Perou, M. T. Lewis, J. M. Rosen & J. C. Chang: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A, 106, 13820-5 (2009)
34. Liu, R., X. Wang, G. Y. Chen, P. Dalerba, A. Gurney, T. Hoey, G. Sherlock, J. Lewicki, K. Shedden & M. F. Clarke: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med, 356, 217-26 (2007) (Pubitemid 46143225)
35. Bertucci, F., N. Cervera & D. Birnbaum: A gene signature in breast cancer. N Engl J Med, 356, 1887-8; author reply 1887-8 (2007)
36. Chang, J. C., E. C. Wooten, A. Tsimelzon, S. G. Hilsenbeck, M. C. Gutierrez, R. Elledge, S. Mohsin, C. K. Osborne, G. C. Chamness, D. C. Allred & P. O'Connell: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 362, 362-9 (2003) (Pubitemid 36957839)
37. Li, X., M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M. F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, H. Wong, J. Rosen & J. C. Chang: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst, 100, 672-9 (2008)
38. Kalluri, R. & R. A. Weinberg: The basics of epithelialmesenchymal transition. J Clin Invest, 119, 1420-8 (2009)
39. Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. Yang & R. A. Weinberg: The epithelialmesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-15 (2008) (Pubitemid 351636299)
40. Gupta, P. B., T. T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R. A. Weinberg & E. S. Lander: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138, 645-59 (2009)
41. Villadsen, R., A. J. Fridriksdottir, L. Ronnov-Jessen, T. Gudjonsson, F. Rank, M. A. LaBarge, M. J. Bissell & O. W. Petersen: Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol, 177, 87-101 (2007) (Pubitemid 46588404)
42. Stingl, J. & C. Caldas: Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer, 7, 791-9 (2007) (Pubitemid 47463670)
43. Prat, A., J. S. Parker, O. Karginova, C. Fan, C. Livasy, J. I. Herschkowitz, X. He & C. M. Perou: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res, 12, R68
44. Muggerud, A. A., M. Hallett, H. Johnsen, K. Kleivi, W. Zhou, S. Tahmasebpoor, R. M. Amini, J. Botling, A. L. Borresen-Dale, T. Sorlie & F. Warnberg: Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol, 4, 357-68
45. Visvader, J. E.: Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev, 23, 2563-77 (2009)
46. Tamimi, R. M., H. J. Baer, J. Marotti, M. Galan, L. Galaburda, Y. Fu, A. C. Deitz, J. L. Connolly, S. J. Schnitt, G. A. Colditz & L. C. Collins: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res, 10, R67 (2008)
47. Bouras, T., B. Pal, F. Vaillant, G. Harburg, M. L. Asselin-Labat, S. R. Oakes, G. J. Lindeman & J. E. Visvader: Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell, 3, 429-41 (2008)
48. Asselin-Labat, M. L., K. D. Sutherland, H. Barker, R. Thomas, M. Shackleton, N. C. Forrest, L. Hartley, L. Robb, F. G. Grosveld, J. van der Wees, G. J. Lindeman & J. E. Visvader: Gata-3 is an essential regulator of mammarygland morphogenesis and luminal-cell differentiation. Nat Cell Biol, 9, 201-9 (2007) (Pubitemid 46420863)
49. Chou, J., S. Provot & Z. Werb: GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol, 222, 42-9
50. Usary, J., V. Llaca, G. Karaca, S. Presswala, M. Karaca, X. He, A. Langerod, R. Karesen, D. S. Oh, L. G. Dressler, P. E. Lonning, R. L. Strausberg, S. Chanock, A. L. Borresen-Dale & C. M. Perou: Mutation of GATA3 in human breast tumors. Oncogene, 23, 7669-78 (2004) (Pubitemid 39424925)
51. Yan, W., Q. J. Cao, R. B. Arenas, B. Bentley & R. Shao: GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem, 285, 14042-51
52. Dydensborg, A. B., A. A. Rose, B. J. Wilson, D. Grote, M. Paquet, V. Giguere, P. M. Siegel & M. Bouchard: GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene, 28, 2634-42 (2009)
53. Yoon, N. K., E. L. Maresh, D. Shen, Y. Elshimali, S. Apple, S. Horvath, V. Mah, S. Bose, D. Chia, H. R. Chang & L. Goodglick: Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol, 41, 1794-1801
54. Johnston, S. R.: New strategies in estrogen receptorpositive breast cancer. Clin Cancer Res, 16, 1979-87
55. Shiu, K. K., R. Natrajan, F. C. Geyer, A. Ashworth & J. S. Reis-Filho: DNA amplifications in breast cancer: genotypic-phenotypic correlations. Future Oncol, 6, 967-84
56. Moasser, M. M.: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene, 26, 6469-87 (2007) (Pubitemid 47530601)
57. Liu, E., A. Thor, M. He, M. Barcos, B. M. Ljung & C. Benz: The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene, 7, 1027-32 (1992)
58. Park, K., S. Han, H. J. Kim, J. Kim & E. Shin: HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology, 48, 702-7 (2006)
59. Casalini, P., M. V. Iorio, E. Galmozzi & S. Menard: Role of HER receptors family in development and differentiation. J Cell Physiol, 200, 343-50 (2004) (Pubitemid 39006925)
60. Rodriguez-Pinilla, S. M., D. Sarrio, E. Honrado, D. Hardisson, F. Calero, J. Benitez & J. Palacios: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res, 12, 1533-9 (2006)
61. Sorlie, T., R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lonning, P. O. Brown, A. L. Borresen-Dale & D. Botstein: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100, 8418-23 (2003) (Pubitemid 36842560)
62. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga & L. Norton: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92 (2001) (Pubitemid 32222155)
63. Esteva, F. J., D. Yu, M. C. Hung & G. N. Hortobagyi: Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol, 7, 98-107 64. Murphy, C. G. & M. Fornier: HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park), 24, 410-5
64. Morrow, P. K., F. Zambrana & F. J. Esteva: Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res, 11, 207 (2009)
65. Gusterson, B. A., D. T. Ross, V. J. Heath & T. Stein: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res, 7, 143-8 (2005) (Pubitemid 40872776)
66. Turner, N. C. & J. S. Reis-Filho: Basal-like breast cancer and the BRCA1 phenotype. Oncogene, 25, 5846-53 (2006)
67. Turner, N. C., J. S. Reis-Filho, A. M. Russell, R. J. Springall, K. Ryder, D. Steele, K. Savage, C. E. Gillett, F. C. Schmitt, A. Ashworth & A. N. Tutt: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 26, 2126-32 (2007) (Pubitemid 46514749)
68. Fillmore, C. M. & C. Kuperwasser: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res, 10, R25 (2008)
69. Lim, E., F. Vaillant, D. Wu, N. C. Forrest, B. Pal, A. H. Hart, M. L. Asselin-Labat, D. E. Gyorki, T. Ward, A. Partanen, F. Feleppa, L. I. Huschtscha, H. J. Thorne, S. B. Fox, M. Yan, J. D. French, M. A. Brown, G. K. Smyth, J. E. Visvader & G. J. Lindeman: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med, 15, 907-13 (2009)
70. Molyneux, G., F. C. Geyer, F. A. Magnay, A. McCarthy, H. Kendrick, R. Natrajan, A. Mackay, A. Grigoriadis, A. Tutt, A. Ashworth, J. S. Reis-Filho & M. J. Smalley: BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell, 7, 403-17
71. Burness, M. L., T. A. Grushko & O. I. Olopade: Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J, 16, 23-32
72. Turner, N., A. Tutt & A. Ashworth: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer, 4, 814-9 (2004) (Pubitemid 39331153)
73. Thompson, M. E., R. A. Jensen, P. S. Obermiller, D. L. Page & J. T. Holt: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet, 9, 444-50 (1995)
74. Jasin, M.: Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene, 21, 8981-93 (2002) (Pubitemid 36110827)
75. Bhattacharyya, A., U. S. Ear, B. H. Koller, R. R. Weichselbaum & D. K. Bishop: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem, 275, 23899-903 (2000) (Pubitemid 30624678)
76. Husain, A., G. He, E. S. Venkatraman & D. R. Spriggs: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res, 58, 1120-3 (1998) (Pubitemid 28183195)
77. Quinn, J. E., R. D. Kennedy, P. B. Mullan, P. M. Gilmore, M. Carty, P. G. Johnston & D. P. Harkin: BRCA1 functions as a differential modulator of chemotherapyinduced apoptosis. Cancer Res, 63, 6221-8 (2003) (Pubitemid 37255167)
78. Abbott, D. W., M. E. Thompson, C. Robinson-Benion, G. Tomlinson, R. A. Jensen & J. T. Holt: BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem, 274, 18808-12 (1999)
79. Isakoff, S. J.: Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J, 16, 53-61
80. Lafarge, S., V. Sylvain, M. Ferrara & Y. J. Bignon: Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene, 20, 6597-606 (2001) (Pubitemid 32980286)
81. Mullan, P. B., J. E. Quinn, P. M. Gilmore, S. McWilliams, H. Andrews, C. Gervin, N. McCabe, S. McKenna, P. White, Y. H. Song, S. Maheswaran, E. Liu, D. A. Haber, P. G. Johnston & D. P. Harkin: BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene, 20, 6123-31 (2001) (Pubitemid 32964424)
82. Tassone, P., S. Blotta, C. Palmieri, S. Masciari, B. Quaresima, M. Montagna, E. D'Andrea, O. P. Eramo, L. Migale, F. Costanzo, P. Tagliaferri & S. Venuta: Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol, 26, 1257-63 (2005)
83. Price, M. & A. N. Monteiro: Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol, 80, 647-53
84. McCabe, N., N. C. Turner, C. J. Lord, K. Kluzek, A. Bialkowska, S. Swift, S. Giavara, M. J. O'Connor, A. N. Tutt, M. Z. Zdzienicka, G. C. Smith & A. Ashworth: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res, 66, 8109-15 (2006) (Pubitemid 44299177)
85. Martin, S. A., C. J. Lord & A. Ashworth: DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev, 18, 80-6 (2008) (Pubitemid 351694447)
86. Anders, C. K., E. P. Winer, J. M. Ford, R. Dent, D. P. Silver, G. W. Sledge & L. A. Carey: Poly(ADP-Ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer. Clin Cancer Res, 16, 4702-10
87. Herschkowitz, J. I., K. Simin, V. J. Weigman, I. Mikaelian, J. Usary, Z. Hu, K. E. Rasmussen, L. P. Jones, S. Assefnia, S. Chandrasekharan, M. G. Backlund, Y. Yin, A. I. Khramtsov, R. Bastein, J. Quackenbush, R. I. Glazer, P. H. Brown, J. E. Green, L. Kopelovich, P. A. Furth, J. P. Palazzo, O. I. Olopade, P. S. Bernard, G. A. Churchill, T. Van Dyke & C. M. Perou: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol, 8, R76 (2007)
88. Gutman, H., R. E. Pollock, N. A. Janjan & D. A. Johnston: Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. J Am Coll Surg, 180, 193-9 (1995)
89. Hennessy, B. T., S. Giordano, K. Broglio, Z. Duan, J. Trent, T. A. Buchholz, G. Babiera, G. N. Hortobagyi & V. Valero: Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol, 17, 605-13 (2006)
90. Hennessy, B. T., S. Krishnamurthy, S. Giordano, T. A. Buchholz, S. W. Kau, Z. Duan, V. Valero & G. N. Hortobagyi: Squamous cell carcinoma of the breast. J Clin Oncol, 23, 7827-35 (2005) (Pubitemid 46657380)
91. Reis-Filho, J. S., F. Milanezi, D. Steele, K. Savage, P. T. Simpson, J. M. Nesland, E. M. Pereira, S. R. Lakhani & F. C. Schmitt: Metaplastic breast carcinomas are basal-like tumours. Histopathology, 49, 10-21 (2006) (Pubitemid 43972916)
92. Hess, K. R., K. Anderson, W. F. Symmans, V. Valero, N. Ibrahim, J. A. Mejia, D. Booser, R. L. Theriault, A. U. Buzdar, P. J. Dempsey, R. Rouzier, N. Sneige, J. S. Ross, T. Vidaurre, H. L. Gomez, G. N. Hortobagyi & L. Pusztai: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol, 24, 4236-44 (2006) (Pubitemid 46630780)
93. Sourvinos, G. & D. A. Spandidos: Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun, 245, 75-80 (1998) (Pubitemid 28414249)
94. Foulkes, W. D., I. M. Stefansson, P. O. Chappuis, L. R. Begin, J. R. Goffin, N. Wong, M. Trudel & L. A. Akslen: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95, 1482-5 (2003) (Pubitemid 37279334)
95. Lakhani, S. R., J. S. Reis-Filho, L. Fulford, F. Penault-Llorca, M. van der Vijver, S. Parry, T. Bishop, J. Benitez, C. Rivas, Y. J. Bignon, J. Chang-Claude, U. Hamann, C. J. Cornelisse, P. Devilee, M. W. Beckmann, C. Nestle-Kramling, P. A. Daly, N. Haites, J. Varley, F. Lalloo, G. Evans, C. Maugard, H. Meijers-Heijboer, J. G. Klijn, E. Olah, B. A. Gusterson, S. Pilotti, P. Radice, S. Scherneck, H. Sobol, J. Jacquemier, T. Wagner, J. Peto, M. R. Stratton, L. McGuffog & D. F. Easton: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res, 11, 5175-80 (2005) (Pubitemid 41003703)
96. Catteau, A., W. H. Harris, C. F. Xu & E. Solomon: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene, 18, 1957-65 (1999) (Pubitemid 29150082)
97. Yang, Q., T. Sakurai, I. Mori, G. Yoshimura, M. Nakamura, Y. Nakamura, T. Suzuma, T. Tamaki, T. Umemura & K. Kakudo: Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer, 92, 54-60 (2001) (Pubitemid 32623040)
98. Furuta, S., X. Jiang, B. Gu, E. Cheng, P. L. Chen & W. H. Lee: Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci U S A, 102, 9176-81 (2005) (Pubitemid 40923537)
99. Liu, S., C. Ginestier, E. Charafe-Jauffret, H. Foco, C. G. Kleer, S. D. Merajver, G. Dontu & M. S. Wicha: BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A, 105, 1680-5 (2008) (Pubitemid 351346574)
100. Xu, X., K. U. Wagner, D. Larson, Z. Weaver, C. Li, T. Ried, L. Hennighausen, A. Wynshaw-Boris & C. X. Deng: Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet, 22, 37-43 (1999) (Pubitemid 29214802)
101. Kouzarides, T.: Chromatin modifications and their function. Cell, 128, 693-705 (2007) (Pubitemid 46273577)
102. Kurdistani, S. K.: Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer, 97, 1-5 (2007) (Pubitemid 47012099)
103. Esteller, M.: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet, 8, 286-98 (2007) (Pubitemid 46439286)
104. Esteller, M.: Aberrant DNA methylation as a cancerinducing mechanism. Annu Rev Pharmacol Toxicol, 45, 629-56 (2005) (Pubitemid 40261820)
105. Brandeis, M., D. Frank, I. Keshet, Z. Siegfried, M. Mendelsohn, A. Nemes, V. Temper, A. Razin & H. Cedar: Sp1 elements protect a CpG island from de novo methylation. Nature, 371, 435-8 (1994) (Pubitemid 24302561)
106. Feinberg, A. P., R. Ohlsson & S. Henikoff: The epigenetic progenitor origin of human cancer. Nat Rev Genet, 7, 21-33 (2006) (Pubitemid 41828945)
107. Baylin, S. B.: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol, 2 Suppl 1, S4-11 (2005)
108. Yang, X., L. Yan & N. E. Davidson: DNA methylation in breast cancer. Endocr Relat Cancer, 8, 115-27 (2001) (Pubitemid 32641353)
109. Shipitsin, M., L. L. Campbell, P. Argani, S. Weremowicz, N. Bloushtain-Qimron, J. Yao, T. Nikolskaya, T. Serebryiskaya, R. Beroukhim, M. Hu, M. K. Halushka, S. Sukumar, L. M. Parker, K. S. Anderson, L. N. Harris, J. E. Garber, A. L. Richardson, S. J. Schnitt, Y. Nikolsky, R. S. Gelman & K. Polyak: Molecular definition of breast tumor heterogeneity. Cancer Cell, 11, 259-73 (2007) (Pubitemid 46349843)
110. Bloushtain-Qimron, N., J. Yao, E. L. Snyder, M. Shipitsin, L. L. Campbell, S. A. Mani, M. Hu, H. Chen, V. Ustyansky, J. E. Antosiewicz, P. Argani, M. K. Halushka, J. A. Thomson, P. Pharoah, A. Porgador, S. Sukumar, R. Parsons, A. L. Richardson, M. R. Stampfer, R. S. Gelman, T. Nikolskaya, Y. Nikolsky & K. Polyak: Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A, 105, 14076-81 (2008)
111. Holm, K., C. Hegardt, J. Staaf, J. Vallon-Christersson, G. Jonsson, H. Olsson, A. Borg & M. Ringner: Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res, 12, R36 (2010)
112. Bediaga, N. G., A. Acha-Sagredo, I. Guerra, A. Viguri, C. Albaina, I. Ruiz Diaz, R. Rezola, M. J. Alberdi, J. Dopazo, D. Montaner, M. de Renobales, A. F. Fernandez, J. K. Field, M. F. Fraga, T. Liloglou & M. M. de Pancorbo: DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res, 12, R77 (2010)
113. Fandy, T. E.: Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem, 16, 2075-85 (2009)
114. Davie, J. R.: Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev, 8, 173-8 (1998) (Pubitemid 28206280)
115. Marks, P., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller & W. K. Kelly: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer, 1, 194-202 (2001) (Pubitemid 33741894)
116. Schneider, R., A. J. Bannister, F. A. Myers, A. W. Thorne, C. Crane-Robinson & T. Kouzarides: Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol, 6, 73-7 (2004) (Pubitemid 38425733)
117. Bernstein, B. E., M. Kamal, K. Lindblad-Toh, S. Bekiranov, D. K. Bailey, D. J. Huebert, S. McMahon, E. K. Karlsson, E. J. Kulbokas, 3rd, T. R. Gingeras, S. L. Schreiber & E. S. Lander: Genomic maps and comparative analysis of histone modifications in human and mouse. Cell, 120, 169-81 (2005) (Pubitemid 40174761)
118. Pokholok, D. K., C. T. Harbison, S. Levine, M. Cole, N. M. Hannett, T. I. Lee, G. W. Bell, K. Walker, P. A. Rolfe, E. Herbolsheimer, J. Zeitlinger, F. Lewitter, D. K. Gifford & R. A. Young: Genome-wide map of nucleosome acetylation and methylation in yeast. Cell, 122, 517-27 (2005) (Pubitemid 41191151)
119. Turner, B. M.: Cellular memory and the histone code. Cell, 111, 285-91 (2002) (Pubitemid 35341385)
120. Jenuwein, T. & C. D. Allis: Translating the histone code. Science, 293, 1074-80 (2001) (Pubitemid 32758077)
121. Fraga, M. F., E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, K. Petrie, N. G. Iyer, A. Perez-Rosado, E. Calvo, J. A. Lopez, A. Cano, M. J. Calasanz, D. Colomer, M. A. Piris, N. Ahn, A. Imhof, C. Caldas, T. Jenuwein & M. Esteller: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet, 37, 391-400 (2005)
122. Wang, G. G., C. D. Allis & P. Chi: Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med, 13, 363-72 (2007) (Pubitemid 47385381)
123. Dhalluin, C., J. E. Carlson, L. Zeng, C. He, A. K. Aggarwal & M. M. Zhou: Structure and ligand of a histone acetyltransferase bromodomain. Nature, 399, 491-6 (1999) (Pubitemid 29258857)
124. Martinez-Balbas, M. A., U. M. Bauer, S. J. Nielsen, A. Brehm & T. Kouzarides: Regulation of E2F1 activity by acetylation. EMBO J, 19, 662-71 (2000) (Pubitemid 30093739)
125. Hyman, E., P. Kauraniemi, S. Hautaniemi, M. Wolf, S. Mousses, E. Rozenblum, M. Ringner, G. Sauter, O. Monni, A. Elkahloun, O. P. Kallioniemi & A. Kallioniemi: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res, 62, 6240-5 (2002) (Pubitemid 35244477)
126. Pollack, J. R., T. Sorlie, C. M. Perou, C. A. Rees, S. S. Jeffrey, P. E. Lonning, R. Tibshirani, D. Botstein, A. L. Borresen-Dale & P. O. Brown: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A, 99, 12963-8 (2002)
127. Pfister, S., S. Rea, M. Taipale, F. Mendrzyk, B. Straub, C. Ittrich, O. Thuerigen, H. P. Sinn, A. Akhtar & P. Lichter: The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer, 122, 1207-13 (2008) (Pubitemid 351287218)
128. Suzuki, J., Y. Y. Chen, G. K. Scott, S. Devries, K. Chin, C. C. Benz, F. M. Waldman & E. S. Hwang: Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res, 15, 3163-71 (2009)
129. Yu, Y., F. Xu, H. Peng, X. Fang, S. Zhao, Y. Li, B. Cuevas, W. L. Kuo, J. W. Gray, M. Siciliano, G. B. Mills & R. C. Bast, Jr.: NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A, 96, 214-9 (1999) (Pubitemid 29036079)
130. Feng, W., Z. Lu, R. Z. Luo, X. Zhang, E. Seto, W. S. Liao & Y. Yu: Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer, 120, 1664-8 (2007) (Pubitemid 46399351)
131. Zhang, Z., H. Yamashita, T. Toyama, H. Sugiura, Y. Omoto, Y. Ando, K. Mita, M. Hamaguchi, S. Hayashi & H. Iwase: HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res, 10, 6962-8 (2004) (Pubitemid 39383047)
132. Saji, S., M. Kawakami, S. Hayashi, N. Yoshida, M. Hirose, S. Horiguchi, A. Itoh, N. Funata, S. L. Schreiber, M. Yoshida & M. Toi: Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene, 24, 4531-9 (2005) (Pubitemid 41032616)
133. Duong, V., C. Bret, L. Altucci, A. Mai, C. Duraffourd, J. Loubersac, P. O. Harmand, S. Bonnet, S. Valente, T. Maudelonde, V. Cavailles & N. Boulle: Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res, 6, 1908-19 (2008)
134. Dalvai, M. & K. Bystricky: The role of histone modifications and variants in regulating gene expression in breast cancer. J Mammary Gland Biol Neoplasia, 15, 19-33 (2010)
135. Elsheikh, S. E., A. R. Green, E. A. Rakha, D. G. Powe, R. A. Ahmed, H. M. Collins, D. Soria, J. M. Garibaldi, C. E. Paish, A. A. Ammar, M. J. Grainge, G. R. Ball, M. K. Abdelghany, L. Martinez-Pomares, D. M. Heery & I. O. Ellis: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res, 69, 3802-9 (2009)
136. Bartel, D. P.: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97 (2004)
137. Lee, R. C., R. L. Feinbaum & V. Ambros: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843-54 (1993) (Pubitemid 24014542)
138. Pasquinelli, A. E., B. J. Reinhart, F. Slack, M. Q. Martindale, M. I. Kuroda, B. Maller, D. C. Hayward, E. E. Ball, B. Degnan, P. Muller, J. Spring, A. Srinivasan, M. Fishman, J. Finnerty, J. Corbo, M. Levine, P. Leahy, E. Davidson & G. Ruvkun: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature, 408, 86-9 (2000)
139. Lagos-Quintana, M., R. Rauhut, J. Meyer, A. Borkhardt & T. Tuschl: New microRNAs from mouse and human. RNA, 9, 175-9 (2003) (Pubitemid 36206285)
140. Aravin, A. A., M. Lagos-Quintana, A. Yalcin, M. Zavolan, D. Marks, B. Snyder, T. Gaasterland, J. Meyer & T. Tuschl: The small RNA profile during Drosophila melanogaster development. Dev Cell, 5, 337-50 (2003) (Pubitemid 37006476)
141. Wightman, B., I. Ha & G. Ruvkun: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75, 855-62 (1993) (Pubitemid 24014543)
142. Lai, E. C.: Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative posttranscriptional regulation. Nat Genet, 30, 363-4 (2002)
143. Hendrickson, D. G., D. J. Hogan, H. L. McCullough, J. W. Myers, D. Herschlag, J. E. Ferrell & P. O. Brown: Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol, 7, e1000238 (2009)
144. Baek, D., J. Villen, C. Shin, F. D. Camargo, S. P. Gygi & D. P. Bartel: The impact of microRNAs on protein output. Nature, 455, 64-71 (2008)
145. Selbach, M., B. Schwanhausser, N. Thierfelder, Z. Fang, R. Khanin & N. Rajewsky: Widespread changes in protein synthesis induced by microRNAs. Nature, 455, 58-63 (2008)
146. Asangani, I. A., S. A. Rasheed, D. A. Nikolova, J. H. Leupold, N. H. Colburn, S. Post & H. Allgayer: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene, 27, 2128-36 (2008)
147. Cloonan, N., M. K. Brown, A. L. Steptoe, S. Wani, W. L. Chan, A. R. Forrest, G. Kolle, B. Gabrielli & S. M. Grimmond: The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol, 9, R127 (2008)
148. Silber, J., D. A. Lim, C. Petritsch, A. I. Persson, A. K. Maunakea, M. Yu, S. R. Vandenberg, D. G. Ginzinger, C. D. James, J. F. Costello, G. Bergers, W. A. Weiss, A. Alvarez-Buylla & J. G. Hodgson: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med, 6, 14 (2008)
149. Calin, G. A., C. Sevignani, C. D. Dumitru, T. Hyslop, E. Noch, S. Yendamuri, M. Shimizu, S. Rattan, F. Bullrich, M. Negrini & C. M. Croce: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 101, 2999-3004 (2004) (Pubitemid 38327724)
150. Negrini, M., D. Rasio, G. M. Hampton, S. Sabbioni, S. Rattan, S. L. Carter, A. L. Rosenberg, G. F. Schwartz, Y. Shiloh, W. K. Cavenee & et al.: Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res, 55, 3003-7 (1995)
151. Lu, J., G. Getz, E. A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B. L. Ebert, R. H. Mak, A. A. Ferrando, J. R. Downing, T. Jacks, H. R. Horvitz & T. R. Golub: MicroRNA expression profiles classify human cancers. Nature, 435, 834-8 (2005) (Pubitemid 40839735)
152. He, L., J. M. Thomson, M. T. Hemann, E. Hernando-Monge, D. Mu, S. Goodson, S. Powers, C. Cordon-Cardo, S. W. Lowe, G. J. Hannon & S. M. Hammond: A microRNA polycistron as a potential human oncogene. Nature, 435, 828-33 (2005) (Pubitemid 40839734)
153. Johnson, S. M., H. Grosshans, J. Shingara, M. Byrom, R. Jarvis, A. Cheng, E. Labourier, K. L. Reinert, D. Brown & F. J. Slack: RAS is regulated by the let-7 microRNA family. Cell, 120, 635-47 (2005) (Pubitemid 40343076)
154. Esquela-Kerscher, A. & F. J. Slack: Oncomirs -microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69 (2006)
155. Cho, W. C.: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer, 6, 60 (2007)
156. Frankel, L. B., N. R. Christoffersen, A. Jacobsen, M. Lindow, A. Krogh & A. H. Lund: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem, 283, 1026-33 (2008)
157. Meng, F., R. Henson, H. Wehbe-Janek, K. Ghoshal, S. T. Jacob & T. Patel: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58 (2007) (Pubitemid 47187346)
158. Chan, J. A., A. M. Krichevsky & K. S. Kosik: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res, 65, 6029-33 (2005) (Pubitemid 40994386)
159. Meng, F., R. Henson, M. Lang, H. Wehbe, S. Maheshwari, J. T. Mendell, J. Jiang, T. D. Schmittgen & T. Patel: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 130, 2113-29 (2006) (Pubitemid 43816961)
160. Iorio, M. V., M. Ferracin, C. G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri, M. Campiglio, S. Menard, J. P. Palazzo, A. Rosenberg, P. Musiani, S. Volinia, I. Nenci, G. A. Calin, P. Querzoli, M. Negrini & C. M. Croce: MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70 (2005) (Pubitemid 41161233)
161. Yu, F., H. Yao, P. Zhu, X. Zhang, Q. Pan, C. Gong, Y. Huang, X. Hu, F. Su, J. Lieberman & E. Song: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-23 (2007) (Pubitemid 350235025)
162. Iliopoulos, D., C. Polytarchou, M. Hatziapostolou, F. Kottakis, I. G. Maroulakou, K. Struhl & P. N. Tsichlis: MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal, 2, ra62 (2009)
163. Mattie, M. D., C. C. Benz, J. Bowers, K. Sensinger, L. Wong, G. K. Scott, V. Fedele, D. Ginzinger, R. Getts & C. Haqq: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer, 5, 24 (2006)
164. Ma, L., J. Teruya-Feldstein & R. A. Weinberg: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449, 682-8 (2007) (Pubitemid 47552092)
165. Huang, Q., K. Gumireddy, M. Schrier, C. le Sage, R. Nagel, S. Nair, D. A. Egan, A. Li, G. Huang, A. J. Klein-Szanto, P. A. Gimotty, D. Katsaros, G. Coukos, L. Zhang, E. Pure & R. Agami: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol, 10, 202-10 (2008) (Pubitemid 351194050)
166. Tavazoie, S. F., C. Alarcon, T. Oskarsson, D. Padua, Q. Wang, P. D. Bos, W. L. Gerald & J. Massague: Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147-52 (2008)
167. Shimono, Y., M. Zabala, R. W. Cho, N. Lobo, P. Dalerba, D. Qian, M. Diehn, H. Liu, S. P. Panula, E. Chiao, F. M. Dirbas, G. Somlo, R. A. Pera, K. Lao & M. F. Clarke: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 138, 592-603 (2009)
168. Pal, A., K. E. Valdez, M. Z. Carletti & F. Behbod: Targeting the perpetrator: breast cancer stem cell therapeutics. Curr Drug Targets, 11, 1147-56 (2010)
169. Park, S. M., A. B. Gaur, E. Lengyel & M. E. Peter: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev, 22, 894-907 (2008) (Pubitemid 351482843)
170. Heo, I., C. Joo, Y. K. Kim, M. Ha, M. J. Yoon, J. Cho, K. H. Yeom, J. Han & V. N. Kim: TUT4 in concert with Lin28 suppresses microRNA biogenesis through premicroRNA uridylation. Cell, 138, 696-708 (2009)
171. Martello, G., A. Rosato, F. Ferrari, A. Manfrin, M. Cordenonsi, S. Dupont, E. Enzo, V. Guzzardo, M. Rondina, T. Spruce, A. R. Parenti, M. G. Daidone, S. Bicciato & S. Piccolo: A MicroRNA targeting dicer for metastasis control. Cell, 141, 1195-207 (2010)
172. Cochrane, D. R., E. N. Howe, N. S. Spoelstra & J. K. Richer: Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol, 2010, 821717
173. Pirollo, K. F., G. Zon, A. Rait, Q. Zhou, W. Yu, R. Hogrefe & E. H. Chang: Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther, 17, 117-24 (2006) (Pubitemid 43100520)
174. Dwyer, R. M., S. M. Potter-Beirne, K. A. Harrington, A. J. Lowery, E. Hennessy, J. M. Murphy, F. P. Barry, T. O'Brien & M. J. Kerin: Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res, 13, 5020-7 (2007) (Pubitemid 47502066)
175. Mercatelli, N., V. Coppola, D. Bonci, F. Miele, A. Costantini, M. Guadagnoli, E. Bonanno, G. Muto, G. V. Frajese, R. De Maria, L. G. Spagnoli, M. G. Farace & S. A. Ciafre: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One, 3, e4029 (2008)